Key Takeaway: Acrivon has reported its financial results for Q2 2026, highlighting the progress of its clinical trials. The ACR-368 Phase 2b interim analysis is scheduled for the second half of 2026, while the ACR-2316 trial is advancing into a randomized dose expansion phase. The promising safety data from ACR-2316 supports its continued development.
Market Sentiment Analysis
POSITIVE FACTORS
ACR-368 Phase 2b interim analysis is on track for H2 2026.
Promising safety profile for ACR-2316 in Phase 1/2 trial.
Upcoming clinical data catalysts could enhance investor interest.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+38%
120-day peak, hindsight
Typical move
7.5%
average across 3 past catalysts
Cash runway
~15 mo
Low dilution risk
Lead asset
ACR-2316
Phase 1 · Specific Advanced Solid Tumors
Full Press Release Details
ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026 ACR-2316 Phase 1/2 trial in AP3-prioritized tumor types advancing in randomized dose expansion phase supported by a promising, favorable safety
Frequently Asked Questions
What are the key highlights from Acrivon's Q2 2026 report?
Acrivon's Q2 2026 report highlights the progress of ACR-368 and ACR-2316 trials.
When is the interim analysis for ACR-368 scheduled?
The interim analysis for ACR-368 is scheduled for the second half of 2026.
What phase is ACR-2316 currently in?
ACR-2316 is currently in the randomized dose expansion phase of its Phase 1/2 trial.
What type of cancer is ACR-368 targeting?
ACR-368 is targeting serous endometrial cancer (EC) treatment arms.